Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist.

Jocelyn M BischofLex H T Van Der PloegWilliam F ColmersRachel Wevrick

Published in: British journal of pharmacology (2016)

Setmelanotide may be a useful investigational hormone/neuropeptide replacement therapy for PWS and rare monogenic forms of obesity exhibiting impaired function of POMC neurons.

Keyphrases

high fat diet induced
insulin resistance
metabolic syndrome
weight loss
spinal cord
type diabetes
cancer therapy
weight gain
adipose tissue
phase ii
skeletal muscle
randomized controlled trial
drug delivery
spinal cord injury
wild type